Clinical trial
Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver…
NCT00394992 · Dutch Colorectal Cancer Group, Other · Terminated
Key facts
| NCT number | NCT00394992 |
|---|---|
| Title | Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer |
| Official title | Randomized Phase III Study Post Radical Resection of Liver Metastasis of Colorectal Cancer: Bevacizumab in Combination With XELOX as Adjuvant Chemotherapy vs XELOX Alone |
| Lead sponsor | Dutch Colorectal Cancer Group, Other |
| Collaborators | Sanofi Industry Roche Pharma AG |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Liver Metastases |
| Intervention type | Drug |
| Interventions | oxaliplatin+capecitabine, Oxaliplatin+capecitabine+bevacizumab |
| Enrollment | 79 |
| Start date | Dec 1, 2006 |
| Primary completion | Aug 1, 2013 |
| Completion | Aug 1, 2013 |
| First posted | Nov 2, 2006 |
| Last update posted | Feb 4, 2014 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: